Accelerate Diagnostics (GB:0H8E)

Accelerate Diagnostics (0H8E) Stock Price & Analysis


0H8E Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.46 - $3.56
Previous Close$0.48
Average Volume (3M)3.12K
Market Cap
Enterprise Value$71.06M
Total Cash (Recent Filing)$55.39M
Total Debt (Recent Filing)$76.90M
Price to Earnings (P/E)-0.5
Mar 29, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding99,099,480
10 Day Avg. Volume1,118
30 Day Avg. Volume3,120
Standard Deviation0.23
Financial Highlights & Ratios
Price to Book (P/B)-4.92
Price to Sales (P/S)113.59
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.42
Enterprise Value/Gross Profit-186.52
Enterprise Value/Ebitda-1.14
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1




What was Accelerate Diagnostics’s price range in the past 12 months?
Accelerate Diagnostics lowest stock price was $0.46 and its highest was $3.56 in the past 12 months.
    What is Accelerate Diagnostics’s market cap?
    Currently, no data Available
    When is Accelerate Diagnostics’s upcoming earnings report date?
    Accelerate Diagnostics’s upcoming earnings report date is Mar 29, 2023 which is tomorrow.
      How were Accelerate Diagnostics’s earnings last quarter?
      Accelerate Diagnostics released its earnings results on Nov 14, 2022. The company reported -$0.167 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.028.
        Is Accelerate Diagnostics overvalued?
        According to Wall Street analysts Accelerate Diagnostics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Accelerate Diagnostics pay dividends?
          Accelerate Diagnostics does not currently pay dividends.
          What is Accelerate Diagnostics’s EPS estimate?
          Accelerate Diagnostics’s EPS estimate is -$0.15.
            How many shares outstanding does Accelerate Diagnostics have?
            Accelerate Diagnostics has 99,099,480 shares outstanding.
              What happened to Accelerate Diagnostics’s price movement after its last earnings report?
              Accelerate Diagnostics reported an EPS of -$0.167 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Accelerate Diagnostics?
                Among the largest hedge funds holding Accelerate Diagnostics’s share is Oracle Investment Management Inc. It holds Accelerate Diagnostics’s shares valued at 1M.


                  Accelerate Diagnostics Stock Smart Score

                  The Accelerate Diagnostics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Accelerate Diagnostics

                  Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Sensus Healthcare
                  Asensus Surgical
                  Accelerate Diagnostics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis